EVG.L
Evgen Pharma plc [EVG.L] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
EVG.L Stock Summary
In the News
EVG.L Financial details
Company Rating
-
Market Cap
2.13M
Income
-6.71M
Revenue
838K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
10
Optionable
No
Shortable
Yes
Earnings
15 Apr 2024
P/E
-1.35
Forward P/E
-
PEG
-0.09
P/S
5.41
P/B
1.15
P/C
-
P/FCF
-1.29
Quick Ratio
10.39
Current Ratio
10.39
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.02
EPS next Y
-
EPS next Q
-
EPS this Y
48.48%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-10.41%
EPS Q/Q
-23.19%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-77%
ROE
-72%
ROC
-1.1%
Gross Margin
-516%
Oper. Margin
-518%
Profit Margin
-400%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.7-4.05
52W High
-
52W Low
-
RSI
-
Rel Volume
0.13
Avg Volume
1.69M
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
1.442
-
-
Volatility
0.03%, 0.03%
Prev Close
-
Price
-
Change
-
Company Profile
- Volume Average 1.69M
- Market Capitalization 2.13M
- Employee 10
- CEO Dr. Huw Jones BSc, Ph.D.
- Headquarters Nether Alderley,GB
- IPO Date 2015-10-21
-
Website
https://evgen.com 
Evgen Pharma plc, a clinical stage drug development company, focuses on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases. It develops its products using Sulforadex, a sulforaphane stabilization technology. The company's lead product is SFX-01, that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase Ib/IIa clinical trials for the treatment of glioblastoma, as well as in preclinical stage for the treatment of haematological malignancies and analogues. It also provides out-licensing of its technology services. Evgen Pharma plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.
